AIM ImmunoTech Files 2024 10-K
Ticker: AIM · Form: 10-K · Filed: Mar 27, 2025 · CIK: 946644
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
AIM ImmunoTech dropped its 2024 10-K. Shows financials for 2024, 2023, 2022. Stock details included.
AI Summary
AIM ImmunoTech Inc. filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Hemispherx Biopharma Inc., is focused on biological products. Key financial data and details about its preferred and common stock, additional paid-in capital, and retained earnings for the fiscal years 2022, 2023, and 2024 are included in the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of AIM ImmunoTech's financial performance and position for the fiscal year 2024, including details on its capital structure.
Risk Assessment
Risk Level: medium — As a biotechnology company, AIM ImmunoTech faces inherent risks related to drug development, regulatory approvals, and market adoption, which are typical for the industry.
Key Numbers
- 2024 — Fiscal Year End (The primary period covered by the 10-K filing.)
- 2023 — Prior Fiscal Year End (Comparative financial data is provided for this year.)
- 2022 — Prior Fiscal Year End (Comparative financial data is provided for this year.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Filer of the 10-K
- Hemispherx Biopharma Inc. (company) — Former name of AIM ImmunoTech Inc.
- 2024-12-31 (date) — Fiscal year end for the reported period
- 2025-03-27 (date) — Filing date of the 10-K
- 2023-12-31 (date) — Prior fiscal year end
- 2022-12-31 (date) — Prior fiscal year end
FAQ
What is the primary business of AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is primarily involved in the business of biological products, specifically in the area of biological products (no diagnostic substances) with SIC code 2836.
When was the 10-K filing submitted to the SEC?
The 10-K filing for AIM ImmunoTech Inc. was submitted to the SEC on March 27, 2025.
What fiscal year does this 10-K report cover?
This 10-K report covers the fiscal year ending December 31, 2024.
What was AIM ImmunoTech Inc. formerly known as?
AIM ImmunoTech Inc. was formerly known as Hemispherx Biopharma Inc., with a date of name change on June 14, 1995.
What types of stock and capital accounts are detailed in the filing for the fiscal years 2022-2024?
The filing details Series A Junior Participating Preferred Stock, Series B Convertible Preferred Stock, Series B Preferred Stock, Common Stock, Additional Paid-In Capital, and Retained Earnings for the fiscal years ending December 31, 2022, 2023, and 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding AIM ImmunoTech Inc. (AIM).